Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN
BACKGROUND: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. METHODS: In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. RESULTS: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. CONCLUSIONS: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
Authors
- Gema Ariceta (ORCID: https://orcid.org/0000-0003-1763-1098)
- Johan Szamosi
- Andrew S. Bomback (ORCID: https://orcid.org/0000-0001-5449-1667)
- Daniel Zecher (ORCID: https://orcid.org/0000-0002-2123-0310)
- Nabil Ziad Melhem (ORCID: https://orcid.org/0009-0006-4776-2653)
- Giuseppe Remuzzi (ORCID: https://orcid.org/0000-0002-6194-3446)
- Seung Hyeok Han (ORCID: https://orcid.org/0000-0001-7923-5635)
- Larry A. Greenbaum (ORCID: https://orcid.org/0000-0002-2490-021X)
- Masashi Mizuno (ORCID: https://orcid.org/0000-0003-3235-6880)
- Carla Nester (ORCID: https://orcid.org/0000-0002-0629-7576)
- Antonio Mastrangelo (ORCID: https://orcid.org/0000-0001-5700-7439)
- Nicole C. A. J. van de Kar (ORCID: https://orcid.org/0000-0002-1990-1189)
- Moglie Le Quintrec (ORCID: https://orcid.org/0000-0002-5857-1207)
- Bradley P. Dixon (ORCID: https://orcid.org/0000-0003-3704-0922)
- Eliyahu V. Khankin (ORCID: https://orcid.org/0000-0002-1695-7267)
- Yael Borovitz (ORCID: https://orcid.org/0000-0001-6708-629X)
- Yahsou Delmas (ORCID: https://orcid.org/0000-0002-5814-3122)
- Marina Vivarelli (ORCID: https://orcid.org/0000-0002-2448-1959)
- Daniel Philip Gale (ORCID: https://orcid.org/0000-0002-9170-1579)
- Dean Wallace
- Nicole M. Isbel (ORCID: https://orcid.org/0000-0002-9566-7179)
- Zhongshen Wang
- Christoph P. B. Licht (ORCID: https://orcid.org/0000-0003-4168-3277)
- Maria Izabel de Holanda (ORCID: https://orcid.org/0000-0003-3758-4946)
- Matthew Caleb Pickering (ORCID: https://orcid.org/0000-0002-1153-0192)
- Fádi Fakhouri (ORCID: https://orcid.org/0000-0001-5390-8002)
- Elena Surova (ORCID: https://orcid.org/0009-0003-3258-5162)
- Patrick D. Walker (ORCID: https://orcid.org/0000-0002-1347-9765)
Institutions
- University of Iowa (US)
- Biogen (United States) (US)
- Emory University (US)
- The University of Queensland (AU)
- University of Toronto (CA)
- Yonsei University (KR)
- Mario Negri Institute for Pharmacological Research (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Columbia University Irving Medical Center (US)
- Hospital for Sick Children (CA)
- Princess Alexandra Hospital (AU)
- Centre Hospitalier Universitaire Vaudois (CH)
- Radboud University Medical Center (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- University Hospital Regensburg (DE)
- Arkana Laboratories (US)
- Centre Hospitalier Universitaire de Montpellier (FR)
- University of Iowa Stead Family Children’s Hospital (US)
- Schneider Children's Medical Center (IL)
- Amalia Kinderziekenhuis (NL)
- Bambino Gesù Children's Hospital (IT)
- Hospital Geral de Bonsucesso (BR)
- Vall d'Hebron Hospital Universitari (ES)
- Hôpital Lapeyronie (FR)
- Swedish Orphan Biovitrum (Sweden) (SE)
- Evelina London Children's Healthcare (GB)
- Royal Manchester Children's Hospital (GB)
- University College London (GB)
- Imperial College London (GB)
- University of Colorado Anschutz Medical Campus (US)
- Nagoya University (JP)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of the American Society of Nephrology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1681/asn.0000001296
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00